Ranbaxy Laboratories launches generic versions of Atorvastatin tablets

06 Mar 2012 Evaluate

Ranbaxy Laboratories (Ranbaxy) has launched the generic versions of Atorvastatin tablets, 10mg, 20mg, 40mg and 80mg in Italy and Sweden and 10mg, 20mg and 40mg in the Netherlands, after receiving approval from the respective local regulatory authorities. In accordance with Ranbaxy’s settlement agreement with Pfizer, it has introduced the product ahead of the applicable patent expiries. Pfizer's patent expires in Italy on May 08, 2012 and in the Netherlands and Sweden on May 06, 2012.

Atorvastatin, a cholesterol reducing drug, is the largest selling pharmaceutical product in Italy with sales of $377 million, as per IMS MAT December, 2011. The market size for Atorvastatin in the Netherlands is $164.4 million, as per IMS MAT December, 2011 and in Sweden it is $55 million, as per IMS MAT December 2011 and is the largest selling Statin product in these two markets.

Ranbaxy will be promoting the drug directly to all channel partners including retail pharmacies and wholesalers in Italy and the Netherlands. In Sweden the company will be offering its drug through the official pricing and reimbursement scheme covering generic medicines, to all retail pharmacies.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×